Clinical trial OX2016-203-01

An open-label, dose-escalation, phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors

Cancers	Urological and male genital cancers Thyroid cancers Lung and thorax cancers Breast cancers Rare tumours Prostate cancers Skin cancers Head and neck cancers Neuroendocrine tumours Gynaecological cancers Liver cancers Digestive cancers Colorectal cancers Brain tumours
Organ	Multiple
Trial status	Trial closed
Investigator	Nuria Kotecki
Trial type	Interventional with experimental drug
Phase	Trial phase 1
Academic trial	Non
Sponsor	Onxeo
EudraCT Identifier	2017-000088-34
ClinicalTrials.gov	https://clinicaltrials.gov/ct2/show/NCT03579628
Inclusion criteria	Any line/RECIST v1.1/Eligible for platinium salt chemotherapy
Last update	04/04/2022